# Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

> **NCT03477864** · PHASE1 · WITHDRAWN · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University**

## Conditions studied

- Stage III Prostate Cancer
- Stage IIIA Prostate Cancer
- Stage IIIB Prostate Cancer
- Stage IIIC Prostate Cancer
- Stage IV Prostate Cancer
- Stage IVA Prostate Cancer
- Stage IVB Prostate Cancer

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT)
- **PROCEDURE:** Radical Prostatectomy
- **BIOLOGICAL:** Anti-PD-1 Monoclonal Antibody REGN2810

## Key facts

- **NCT ID:** NCT03477864
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-12-24
- **Primary completion:** 2019-11-04
- **Final completion:** 2019-11-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was not accruing
- **Last updated:** 2025-04-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03477864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03477864, "Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03477864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*